Gentium S.p.A. Receives Negative Opinion From the CHMP on Defibrotide for the Treatment and Prevention of VOD

VILLA GUARDIA, Italy, March 22, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it has been informed by the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP") that it has adopted a negative opinion, recommending the refusal of the marketing authorization for Defibrotide to treat and prevent hepatic veno-occlusive disease ("VOD") in adults and children undergoing hematopoietic stem cell transplantation therapy.